The "Valley of Death" remains a formidable barrier in biomedicine, where countless promising scientific discoveries fail to translate into viable therapeutics. This seminar will address the critical challenges that cause this attrition, spanning the entire value chain from initial target validation and compound generation to preclinical and clinical assessments of safety and efficacy.

We will examine common pitfalls in translational science and medicine, unraveling the scientific, technical, and cultural mindset gaps that underpin these obstacles. Finally, we will explore the evolving landscape of novel approaches designed to bridge this valley, focusing on how multinational pharmaceutical companies are deploying innovative external innovation models to enhance productivity and success rates in drug discovery and development.